Bioburden Reduction of Diabetic Foot Ulcer

Noveon Laser Treatment to Effect Bioburden Reduction or Elimination in Diabetic Foot Ulcer: A Davice Performance Clinical Study

Status

UNKNOWN

Phases

Phase 1

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00776854

Enrollment

Registered

2008-10-21

Start date

2008-11-30

Completion date

2009-11-30

Last updated

2008-10-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetic Foot Ulcer

Brief summary

Study to see if a laser can get rid of bacateria called MRSA in your diabetic ulcer

Interventions

DEVICENoveon laser

870 and 930nm wavelengths

Study design

Allocation

NON_RANDOMIZED

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to 70 Years

Healthy volunteers

Inclusion criteria

* 18 and older * Diabetic foot ulcer * MRSA positive

Exclusion criteria

osteomylelitis pregnancy allery to e mycin \-

Design outcomes

Primary

Measure	Time frame
Decrease of Bioburden Effect In diabetic Foot Ulcer	28 days

Countries

United States

Contacts

Primary ContactAlan Robbins, MD

alanhrobbins@comcast.com781-893-1000

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026